Discussing Baricitinib for Alopecia Areata

Opinion Video Author(s): Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment for severe alopecia areata (AA). Video content above is prompted by the following: Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics. A Population Health Approach to Managing Heart Failure A Population Health Approach to Managing Heart Failure 2 Commerce DriveSuite 100Cranbury, NJ 08512 © 2025 MJH Life Sciences® and AJMC®. All rights reserved.